Oregon State University’s Dr. David Dallas will present published data showing that vessel pasteurization preserves the bioactive proteins of human milk more than ultra-high temperature and autoclave sterilization.
DUARTE, California, December 5, 2022 /PRNewswire/ — Prolacta Bioscience®The world’s leading hospital provider of 100% human milk-based nutritional products for critically ill premature infants today, PhD, of Oregon State University. David Dallas will present published data on the effects of various production methods on bioactive proteins. In donor human milk at 12:15 p.m. on Tuesday, December 6 at the Hot Topics in Neonalogy® 2022 conference in National Harbor, Maryland.
Sponsored by Nemours Child Health, Hot Topics in Neonatology was the first neonatal conference to have attended over 1,000 neonatologists and perinatologists from around the world in over 30 years.
Dr. Dallas’ presentation will summarize data published in September in the peer-reviewed journal Boundaries in Nutrition. Paper, “Structural and Functional Changes of Bioactive Proteins in Donor Human Milk Processed by In-Boat Pasteurization, Autoclave Sterilization, Ultra-High Temperature Sterilization, Freeze-thaw, and Homogenization” includes findings showing that vessel pasteurization preserves the bioactive proteins of human milk more than ultra-high-temperature (UHT) or retort sterilization.one
“Our findings provide information to provide babies with donor milk that is better matched to breast milk to support their growth and development,” Dallas said.
Melinda Elliott, Prolacta and Chief Medical Officer, said, “Dr. is a practicing neonatologist. We invite the community to attend the symposium to learn more about how processing techniques affect bioactivity.”
About Human Milk-Based Nutritional Products
The major difference between cow’s milk-based and human milk-based nutritional products is the composition, specifically the bioactive components specific to human milk. These include immunoglobulins, lactoferrin, milk fat globule membrane, and a wide range of prebiotics known as human milk oligosaccharides (HMOs), which are not readily produced and are therefore greatly reduced or deficient in cow’s milk-based nutritional products.2 Bioactivity is thought to support the immunity, development, growth and long-term health of infants.3
Prolacta’s 100% human milk-based nutritional products have the highest bioactivity in the human milk industry.one Prolacta’s nutritional products are pasteurized onboard using profiles defined by the US Food and Drug Administration (FDA) to ensure pathogen inactivation and the highest level of safety while preserving as much of the milk’s natural bioactivity as possible.4 Prolacta’s inboard pasteurized products have higher bioactivity than products processed using other methods, including retort sterilization and UHT processing.1,5,6
About Prolacta Bioscience
Prolacta Bioscience® Inc. is a privately held global life sciences company dedicated to Advancing Human Milk Science® to improve the health of critically ill, premature babies. Prolacta’s 100% human milk-based nutritional products have been evaluated in more than 20 clinical trials published in peer-reviewed journals. To date, more than 80,000 premature babies worldwide have benefited from Prolacta’s nutritional products.7 Established in 1999, Prolacta is the world’s leading provider of human milk-based nutritional products for hospital use while also exploring the therapeutic potential of human milk in a wide range of diseases. Prolacta maintains the industry’s strictest quality and safety standards for screening, testing and processing of donor human milk. Operating the world’s first pharmaceutical grade human milk processing facilities, Prolacta uses vessel pasteurization and an FDA-reviewed patented manufacturing process to ensure pathogen inactivation while preserving the nutritional composition and bioactivity of its human milk-based products. Prolacta is a global company headquartered in Duarte, California and can be found online at www.prolacta.com. twitterInstagram, Facebook and LinkedIn.
- Liang N, Koh J, Kim BJ et al. Structural and functional changes of bioactive proteins in donor human milk processed by jar pasteurization, retort sterilization, ultra-high temperature sterilization, freeze-thaw and homogenization. Front Nutr. Released online on September 15, 2022. doi:10.3389/fnut.2022.926814
- Ballard O, Morrow AL. Composition of breast milk: nutrients and bioactive factors. Pediatric Clinic North Am. 2013 Feb;60(1):49-74. doi:10.1016/j.pcl.2012.10.001. PMID: 23178060; PMCID: PMC3586783.
- Gila-Diaz A, Arribas SM, Algara A, Martín-Cabrejas MA, López de Pablo ÁL, Sáenz de Pipaón M, Ramiro-Cortijo D. A review of bioactive factors in human breast milk: a focus on prematurity. nutrients. 2019;11(6):1307. doi:10.3390/nu11061307
- Data in file.
- Meredith-Dennis L, Xu G, Goonatilleke E, Lebrilla CB, Underwood MA, Smilowitz JT. Composition and variation of macronutrients, immune proteins and human milk oligosaccharides in human milk from non-profit and commercial milk banks. J Hum Lactate. 2018;34(1):120-129. doi:10.1177/0890334417710635
- Lima HK, Wagner-Gillespie M, Perrin MT, Fogleman AD. Bacteria and bioactivity in Holder pasteurized and shelf-stable breast milk products. Curr Giant Nutr. 2017;1(8):e001438. doi:10.3945/cdn.117.001438
- Data in the file; Estimated number of premature babies fed with Prolacta products from January 2007 to December 2021.
View original content to download multimedia: https://www.prnewswire.com/news-releases/hot-topics-in-neonatology-2022-conference-will-include-symposium-on-benefits-of-vat-pasteurization-for -human-donor-milk-301692947.html
SOURCE Prolacta Bioscience